USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. reduced its position in USANA Health Sciences, Inc. (NYSE:USNA) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,616 shares of the company’s stock after selling 1,400 shares during the period. Alliancebernstein L.P. owned about 0.07% of USANA Health Sciences worth $489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in USNA. State Street Corp increased its position in shares of USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company’s stock valued at $16,501,000 after acquiring an additional 2,782 shares during the last quarter. Barclays PLC lifted its position in USANA Health Sciences by 111.9% during the 3rd quarter. Barclays PLC now owns 27,737 shares of the company’s stock worth $1,052,000 after acquiring an additional 14,647 shares during the period. Geode Capital Management LLC lifted its holdings in USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after acquiring an additional 12,898 shares during the period. Franklin Resources Inc. grew its stake in USANA Health Sciences by 9.2% in the 3rd quarter. Franklin Resources Inc. now owns 21,050 shares of the company’s stock valued at $750,000 after acquiring an additional 1,771 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of USANA Health Sciences by 5.7% in the fourth quarter. Nordea Investment Management AB now owns 50,450 shares of the company’s stock valued at $1,814,000 after purchasing an additional 2,723 shares during the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other USANA Health Sciences news, CEO Jim Brown sold 5,000 shares of USANA Health Sciences stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the sale, the chief executive officer now directly owns 15,716 shares in the company, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joshua Foukas sold 5,732 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock valued at $500,285 over the last three months. 0.63% of the stock is owned by insiders.

USANA Health Sciences Stock Up 1.3 %

NYSE:USNA opened at $23.75 on Monday. The stock has a fifty day simple moving average of $28.44 and a 200 day simple moving average of $33.53. The firm has a market capitalization of $448.90 million, a price-to-earnings ratio of 8.39, a price-to-earnings-growth ratio of 0.93 and a beta of 1.00. USANA Health Sciences, Inc. has a 1-year low of $23.26 and a 1-year high of $49.78.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Equities analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on USNA shares. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Finally, DA Davidson cut their price objective on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.